{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:52:08Z","timestamp":1788821528930,"version":"build-2803163510"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0018_s_001a_w2aab3b7b2b1b6b1aab1c16b1Aa\">\n                    <jats:title id=\"d2883964e3862_w2aab3b7b2b1b6b1aab1c16b1aAa\">Background<\/jats:title>\n                    <jats:p>Combining cytoreductive surgery (CRS) with Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) can benefit patients with peritoneal metastasis from colorectal cancer. The present study evaluates the small bowel subset of the Peritoneal Cancer Index (Small-Bowel-PCI score (SB-PCI), min-max 0\u201312) as a prognostic factor in such patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0018_s_002b_w2aab3b7b2b1b6b1aab1c16b2Aa\">\n                    <jats:title id=\"d2883964e3871_w2aab3b7b2b1b6b1aab1c16b2aAa\">Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients that underwent CRS and HIPEC for recurrent colorectal cancer with peritoneal metastasis. Patient characteristics, procedure details, and clinical outcomes were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0018_s_003c_w2aab3b7b2b1b6b1aab1c16b3Aa\">\n                    <jats:title id=\"d2883964e3880_w2aab3b7b2b1b6b1aab1c16b3aAa\">Results<\/jats:title>\n                    <jats:p>Eighty patients were included. The mean intraoperative PCI-score was 16.8, with a mean SB-PCI score of 5.9. CC0\/1 was achieved in 62\/80 patients. The mean follow-up period was 26.3\u2006months. Univariate regression analysis showed that the ECOG status, the presence of severe complications, the HIPEC regimen (oxaliplatin vs. mitomycin-C), the PCI score, the SB-PCI score and the completeness of cytoreduction correlated significantly with overall survival. In multivariate analysis, the SB-PCI and CC score were identified as independent prognostic factors of survival. When the SB-PCI was stratified in three groups (0\u20134, 5\u20138 and 9\u201312), Kaplan\u2013Meier curve analysis showed significant difference in survival (p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0018_s_004d_w2aab3b7b2b1b6b1aab1c16b4Aa\">\n                    <jats:title id=\"d2883964e3889_w2aab3b7b2b1b6b1aab1c16b4aAa\">Conclusions<\/jats:title>\n                    <jats:p>The SB-PCI correlates with overall survival in patients with peritoneal metastases secondary to colorectal cancer in this retrospective cohort. Its use should be validated in prospective patient series.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0018","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T05:03:57Z","timestamp":1572411837000},"source":"Crossref","is-referenced-by-count":24,"title":["CRS and HIPEC in patients with peritoneal metastasis secondary to colorectal cancer: The small-bowel PCI score as a predictor of survival"],"prefix":"10.1515","volume":"4","author":[{"given":"John","family":"Spiliotis","sequence":"first","affiliation":[{"name":"Department of Peritoneal Surface Oncology , Athens Medical Centre , Athens , Attica , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Kalles","sequence":"additional","affiliation":[{"name":"Department of Surgery , Naval Hospital of Athens , Deinokratous 70 , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kyriazanos","sequence":"additional","affiliation":[{"name":"Department of Surgery , Naval Hospital of Athens , Deinokratous 70 , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexios","family":"Terra","sequence":"additional","affiliation":[{"name":"Department of Surgery , Metaxa Cancer Hospital of Piraeus , Piraeus , Attike , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Prodromidou","sequence":"additional","affiliation":[{"name":"Department of Surgery , Metaxa Cancer Hospital of Piraeus , Piraeus , Attike , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Raptis","sequence":"additional","affiliation":[{"name":"Department of Peritoneal Surface Oncology , Athens Medical Centre , Athens , Attica , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kopanakis","sequence":"additional","affiliation":[{"name":"Department of Surgery , Metaxa Cancer Hospital of Piraeus , Piraeus , Attike , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Christopoulou","sequence":"additional","affiliation":[{"name":"Department of Oncology , Saint Andreas General Hospital , Patras , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"2025120909222923499_j_pp-2019-0018_ref_001_w2aab3b7b2b1b6b1ab1b5b1Aa","doi-asserted-by":"crossref","unstructured":"Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA: Cancer J Clin 2014;64:104\u201317.24639052","DOI":"10.3322\/caac.21220"},{"key":"2025120909222923499_j_pp-2019-0018_ref_002_w2aab3b7b2b1b6b1ab1b5b2Aa","doi-asserted-by":"crossref","unstructured":"Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011;128:2717\u201325.2071516710.1002\/ijc.25596","DOI":"10.1002\/ijc.25596"},{"key":"2025120909222923499_j_pp-2019-0018_ref_003_w2aab3b7b2b1b6b1ab1b5b3Aa","doi-asserted-by":"crossref","unstructured":"Aoyagi T, Terracina KP, Raza A, Takabe K. Current treatment options for colon cancer peritoneal carcinomatosis. World J Gastroenterol 2014;20:12493\u2013500.2525394910.3748\/wjg.v20.i35.12493","DOI":"10.3748\/wjg.v20.i35.12493"},{"key":"2025120909222923499_j_pp-2019-0018_ref_004_w2aab3b7b2b1b6b1ab1b5b4Aa","doi-asserted-by":"crossref","unstructured":"Passot G, Bakrin N, Roux AS, Vaudoyer D, Gilly FN, Glehen O, et al. Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Onco 2014;40:529\u201335.10.1016\/j.ejso.2013.11.019","DOI":"10.1016\/j.ejso.2013.11.019"},{"key":"2025120909222923499_j_pp-2019-0018_ref_005_w2aab3b7b2b1b6b1ab1b5b5Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Review of a personal experience in the management of carcinomatosis and sarcomatosis. Jpn J Clin Oncol 2001;31:573\u201383.1190248710.1093\/jjco\/hye088","DOI":"10.1093\/jjco\/hye088"},{"key":"2025120909222923499_j_pp-2019-0018_ref_006_w2aab3b7b2b1b6b1ab1b5b6Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol: Off J Am Soc Clin Oncol 2009;27:681\u20135.10.1200\/JCO.2008.19.7160","DOI":"10.1200\/JCO.2008.19.7160"},{"key":"2025120909222923499_j_pp-2019-0018_ref_007_w2aab3b7b2b1b6b1ab1b5b7Aa","doi-asserted-by":"crossref","unstructured":"Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol: Off J Am Soc Clin Oncol 2003;21:3737\u201343.10.1200\/JCO.2003.04.187","DOI":"10.1200\/JCO.2003.04.187"},{"key":"2025120909222923499_j_pp-2019-0018_ref_008_w2aab3b7b2b1b6b1ab1b5b8Aa","unstructured":"Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985;98:414\u201322.3898450"},{"key":"2025120909222923499_j_pp-2019-0018_ref_009_w2aab3b7b2b1b6b1ab1b5b9Aa","doi-asserted-by":"crossref","unstructured":"Benizri EI, Bernard JL, Rahili A, Benchimol D, Bereder JM. Small bowel involvement is a prognostic factor in colorectal carcinomatosis treated with complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2012;10:56.10.1186\/1477-7819-10-5622494563","DOI":"10.1186\/1477-7819-10-56"},{"key":"2025120909222923499_j_pp-2019-0018_ref_010_w2aab3b7b2b1b6b1ab1b5c10Aa","unstructured":"Sugarbaker P, Deraco M, Glehen O, Helm C, Morris D, Van der Speeten K. Cytoreductive surgery and perioperative chemotherapy for peritoneal surface malignancy: textbook and video atlas. PSOGI 2013;1:1\u201322."},{"key":"2025120909222923499_j_pp-2019-0018_ref_011_w2aab3b7b2b1b6b1ab1b5c11Aa","doi-asserted-by":"crossref","unstructured":"Faron M, Macovei R, Goere D, Honore C, Benhaim L, Elias D. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol 2016;23:114\u20139.2601415810.1245\/s10434-015-4627-8","DOI":"10.1245\/s10434-015-4627-8"},{"key":"2025120909222923499_j_pp-2019-0018_ref_012_w2aab3b7b2b1b6b1ab1b5c12Aa","doi-asserted-by":"crossref","unstructured":"Goere D, Souadka A, Faron M, Cloutier AS, Viana B, Honore C, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 2015;22:2958\u201364.10.1245\/s10434-015-4387-525631064","DOI":"10.1245\/s10434-015-4387-5"},{"key":"2025120909222923499_j_pp-2019-0018_ref_013_w2aab3b7b2b1b6b1ab1b5c13Aa","doi-asserted-by":"crossref","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mcfadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649\u201356.716500910.1097\/00000421-198212000-00014","DOI":"10.1097\/00000421-198212000-00014"},{"key":"2025120909222923499_j_pp-2019-0018_ref_014_w2aab3b7b2b1b6b1ab1b5c14Aa","doi-asserted-by":"crossref","unstructured":"Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205.10.1097\/01.sla.0000133083.54934.ae","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"2025120909222923499_j_pp-2019-0018_ref_015_w2aab3b7b2b1b6b1ab1b5c15Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004;91:747\u201354.10.1002\/bjs.447315164446","DOI":"10.1002\/bjs.4473"},{"key":"2025120909222923499_j_pp-2019-0018_ref_016_w2aab3b7b2b1b6b1ab1b5c16Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol: Off J Am Soc Clin Oncol 2004;22:3284\u201392.10.1200\/JCO.2004.10.012","DOI":"10.1200\/JCO.2004.10.012"},{"key":"2025120909222923499_j_pp-2019-0018_ref_017_w2aab3b7b2b1b6b1ab1b5c17Aa","doi-asserted-by":"crossref","unstructured":"Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004;11:178\u201386.10.1245\/ASO.2004.05.00914761921","DOI":"10.1245\/ASO.2004.05.009"},{"key":"2025120909222923499_j_pp-2019-0018_ref_018_w2aab3b7b2b1b6b1ab1b5c18Aa","doi-asserted-by":"crossref","unstructured":"Da Silva RG, Sugarbaker PH. Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 2006;203:878\u201386.10.1016\/j.jamcollsurg.2006.08.02417116556","DOI":"10.1016\/j.jamcollsurg.2006.08.024"},{"key":"2025120909222923499_j_pp-2019-0018_ref_019_w2aab3b7b2b1b6b1ab1b5c19Aa","doi-asserted-by":"crossref","unstructured":"Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg 2008;248:829\u201335.18948811","DOI":"10.1097\/SLA.0b013e31818a15b5"},{"key":"2025120909222923499_j_pp-2019-0018_ref_020_w2aab3b7b2b1b6b1ab1b5c20Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001;92:71\u20136.10.1002\/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-911443611","DOI":"10.1002\/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9"},{"key":"2025120909222923499_j_pp-2019-0018_ref_021_w2aab3b7b2b1b6b1ab1b5c21Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43:S15\u2013S25.10.1007\/s00280005109310357554","DOI":"10.1007\/s002800051093"},{"key":"2025120909222923499_j_pp-2019-0018_ref_022_w2aab3b7b2b1b6b1ab1b5c22Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Benizri E, Vernerey D, Eldweny H, Dipietrantonio D, Pocard M. Preoperative criteria of incomplete resectability of peritoneal carcinomatosis from non-appendiceal colorectal carcinoma. Gastroenterol Clin Biol 2005;29:1010\u20133.1643550810.1016\/S0399-8320(05)88175-8","DOI":"10.1016\/S0399-8320(05)88175-8"},{"key":"2025120909222923499_j_pp-2019-0018_ref_023_w2aab3b7b2b1b6b1ab1b5c23Aa","doi-asserted-by":"crossref","unstructured":"Chandramohan A, Thrower A, Smith SA, Shah N, Moran B. \u201cPAUSE\u201d: a method for communicating radiological extent of peritoneal malignancy. Clin Radiol 2017;72:972\u201380.2877845410.1016\/j.crad.2017.07.005","DOI":"10.1016\/j.crad.2017.07.005"},{"key":"2025120909222923499_j_pp-2019-0018_ref_024_w2aab3b7b2b1b6b1ab1b5c24Aa","doi-asserted-by":"crossref","unstructured":"Chua TC, Al-Zahrani A, Saxena A, Glenn D, Liauw W, Zhao J, et al. Determining the association between preoperative computed tomography findings and postoperative outcomes after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2011;18:1582\u20139.10.1245\/s10434-010-1492-321207170","DOI":"10.1245\/s10434-010-1492-3"},{"key":"2025120909222923499_j_pp-2019-0018_ref_025_w2aab3b7b2b1b6b1ab1b5c25Aa","doi-asserted-by":"crossref","unstructured":"Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol 2015;22:1708\u201315.2520149910.1245\/s10434-014-4041-7","DOI":"10.1245\/s10434-014-4041-7"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/4\/4\/article-20190018.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0018\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0018\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:57:48Z","timestamp":1765277868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0018\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,11,2]]},"published-print":{"date-parts":[[2019,11,26]]}},"alternative-id":["10.1515\/pp-2019-0018"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0018","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,30]]},"article-number":"20190018"}}